<DOC>
	<DOC>NCT01529372</DOC>
	<brief_summary>The REALISE trial is a single-arm, open-label, prospective, post market evaluation to be conducted on twenty (20) eligible patients with a twelve month follow-up period.</brief_summary>
	<brief_title>REnAL denervatIon by ultraSound Transcatheter Emission</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Resistant hypertension, as defined in the 2007 ESHESC guidelines 18 years of age or older Negative pregnancy test for female patients of childbearing potential Willing and able to comply with followup requirements Signed informed consent Secondary hypertension Main renal arteries length &lt; 20 mm Main renal arteries diameter &lt; 4 mm Renal artery stenosis Iliac/femoral artery stenosis precluding insertion of the catheter Allergy to contrast media Currently participating in the study of an investigational drug or device Hemodynamics abnormality Moderate to severe renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Blood pressure</keyword>
	<keyword>Renal denervation</keyword>
</DOC>